Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
CEL-SCI CORPORATION (NYSE: CVM) Delayed: 1.67 +0.01 (0.60%)
Previous Close $1.66    52 Week High $0.66 
Open $1.71    52 Week Low $0.20 
Day High $1.75    P/E N/A 
Day Low $1.66    EPS $-0.34 
Volume 110,189